Definium Therapeutics, Inc. Proceeds from Long-term Lines of Credit
Definium Therapeutics, Inc. (DFTX) reported Proceeds from Long-term Lines of Credit of $0 for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromLongTermLinesOfCredit · last filed 2026-08-06
- Definium Therapeutics, Inc. proceeds from long-term lines of credit for the quarter ending 2025-12-31 was $0.00.
- Definium Therapeutics, Inc. proceeds from long-term lines of credit for the quarter ending 2025-09-30 was $0.00.
- Definium Therapeutics, Inc. proceeds from long-term lines of credit for the quarter ending 2024-12-31 was $0.00.
- Definium Therapeutics, Inc. proceeds from long-term lines of credit for the quarter ending 2024-09-30 was $0.00.
- Definium Therapeutics, Inc. proceeds from long-term lines of credit for fiscal 2025 was $42.00M, a 320.00% increase from fiscal 2024.
- Definium Therapeutics, Inc. proceeds from long-term lines of credit for fiscal 2024 was $10.00M, a 33.33% decline from fiscal 2023.
- Definium Therapeutics, Inc. proceeds from long-term lines of credit for fiscal 2023 was $15.00M.
| Period end | Proceeds from Long-term Lines of Credit 3 month | Proceeds from Long-term Lines of Credit 6 month | Proceeds from Long-term Lines of Credit 9 month | Proceeds from Long-term Lines of Credit 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-08-06 | |||
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $0.00 derived: sum of 2 quarters · filed 2026-02-26 | $42.00M 10-K · filed 2026-02-26 | |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $42.00M 10-Q · filed 2025-11-06 | ||
| 2025-06-30 | $42.00M 10-Q · filed 2026-08-06 | |||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $0.00 derived: sum of 2 quarters · filed 2026-02-26 | $10.00M 10-K · filed 2026-02-26 | |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $10.00M 10-Q · filed 2025-11-06 | ||
| 2024-06-30 | $10.00M 10-Q · filed 2025-07-31 | |||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | $15.00M 10-K · filed 2025-03-06 | ||
| 2023-09-30 | $15.00M 10-Q · filed 2024-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cronos Group Inc. (CRON) | $1.223B | ||
| Tilray Brands, Inc. (TLRY) | United States | $0.554B | -5.97 |
| Canopy Growth Corp (CGC) | $0.395B | ||
| USANA HEALTH SCIENCES INC (USNA) | United States | $0.264B | -17.90 |
| Niagen Bioscience, Inc. (NAGE) | United States | $0.238B | 15.72 |
| FITLIFE BRANDS, INC. (FTLF) | United States | $0.087B | 16.59 |
| MANNATECH INC (MTEX) | United States | $0.014B | |
| NATURAL ALTERNATIVES INTERNATIONAL INC (NAII) | United States | $0.011B | -1.16 |
| Synergy CHC Corp. (SNYR) | United States | $0.001B | |
| Functional Brands Inc. (MEHA) | United States | $0.001B |